Global clinical trial shows improved survival rates for common childhood leukemia

Early study results were so promising that the trial closed early, with findings published in the New England Journal of Medicine showing a striking 61% reduction in the risk of B-ALL relapse or death for those who received both chemotherapy and blinatumomab.

Read more: https://medicalxpress.com/news/2024-12-global-clinical-trial-survival-common.html